Hematopoiesis News Volume 6.38 | Sep 29 2015

Microbiota from Obese Mice Regulate Hematopoietic Stem Cell Differentiation by Altering the Bone Niche
Investigators showed that high-fat diet decreased long-term Lin^–Sca-1⁺c-Kit⁺ stem cells and shifted lymphoid to myeloid cell differentiation. [Cell Metab] Abstract | Graphical Abstract

NACA Deficiency Reveals the Crucial Role of Somite-Derived Stromal Cells in Hematopoietic Niche Formation
Scientists showed that the stromal cells of the caudal hematopoietic tissue, the first niche where definitive hematopoietic stem/progenitor cells home in zebrafish development, derive from the caudal somites through an epithelial-mesenchymal transition. [Nat Commun] Full Article

Interleukin-2 Critically Regulates Bone Marrow Erythropoiesis and Prevents Anemia Development
The authors showed how essential cytokines of lymphoid cells could exert critical influence on the development of erythrocytes and thus expand the understanding of the complex regulation of hematopoiesis in the bone marrow. [Eur J Immunol] Abstract

Definitive Hematopoietic Multipotent Progenitor Cells Are Transiently Generated from Hemogenic Endothelial Cells in Human Pluripotent Stem Cells
Researchers demonstrated that CD34⁺ CD31⁺ CD144⁺ hemato-endothelial progenitors gave rise to hematopoietic multipotent progenitor cells via hemogenic endothelial cells that exist transiently. [J Cell Physiol] Abstract

The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Improves In Vitro Generation of Highly Functional NK Cells from CD34⁺ Hematopoietic Stem and Progenitor Cells
Investigators demonstrated that addition of aryl hydrocarbon receptor antagonist SR1 to their culture protocol potently enhances expansion of CD34⁺ hematopoietic stem and progenitor cells, and induces expression of natural killer (NK) cell associated transcription factors promoting NK cell differentiation. [Stem Cells Dev] Abstract

Regulation of the Flt3 Gene in Hematopoietic Stem and Early Progenitor Cells
The authors used the conditional deletion of the Myb gene to investigate the influence of MYB in Flt3 transcriptional regulation within the hematopoietic stem cell hierarchy. [PLoS One] Full Article

A CXCR4 Antagonist Leads to Tumor Suppression by Activation of Immune Cells in a Leukemia-Induced Microenvironment
Scientists showed that the CXCR4 antagonist, plerixafor, decreased the level of CXCR4 expression and inhibited SDF-1-induced migration of leukemic cells. [Oncol Rep] Abstract

CLINICAL RESEARCH

Long-Term Outcome and Prognostic Factors of Second Allogeneic Hematopoietic Stem Cell Transplant for Acute Leukemia in Patients with a Median Follow-Up >10 Years
To estimate the long-term results of second allogeneic hematopoietic stem cell transplantation (HSCT2), the authors retrospectively analyzed the course of 286 patients receiving myeloablative HSCT2 between 1985 and 2000, with a median follow-up of 11.3 years. [Bone Marrow Transplant] Abstract

Low Dose Cyclophosphamide Effectively Mobilizes Peripheral Blood Stem Cells in Patients with Autoimmune Disease
The authors assessed the feasibility and efficacy of peripheral blood stem cells mobilization and collection in 35 patients with refractory autoimmune disease. [Eur J Haematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Amgen To Present New Kyprolis^® (carfilzomib) Data At 15th International Myeloma Workshop
Amgen announced the presentation of several studies evaluating Kyprolis^® for injection, a next-generation proteasome inhibitor. [Press release from Amgen discussing research presented at the 15^th International Myeloma Workshop (IMW), Rome] Press Release

From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols. Watch the video.

Amgen Receives CHMP Positive Opinions for Two New Treatment Options for Patients with Blood Cancer in Europe
Amgen announced that the Committee for Medicinal Products (CHMP) for Human Use of the European Medicines Agency adopted positive opinions recommending marketing authorization for Kyprolis^® in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma and BLINCYTO^® for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia. [Amgen] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Position – Hematology and Immunology (University of Liege)

Director of Research – Oncology and Hematology (CancerCare Manitoba)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Regulatory Coordinator – Leukemia (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Hematopoietic Regeneration and Myeloid Malignancies (Weill-Cornell Medical College)

Postdoctoral Position – Hematopoietic Stem and Progenitor Cell Assays (Weill Cornell Medical School)

Research Associate – Cell Biology (Editas Medicine)

Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.